

Results Note – Supermax Trading Buy (TP: RM8.80)

Impressive Quarter to Kick Start

- 1QFY10 bottom line registered RM51.5m (+>100% YoY; +16.8% QoQ) as sales of examination gloves, stayed resilient with higher global demand, particularly from the medical and dental industries. 1Q's Net earnings recorded were way above expectations, 31% of consensus forecast. The robust results were attributed to higher selling prices of gloves by passing its latex cost increase to customer on the back of rising demand and limited supply. No dividend was declared.
- **Topline surged to RM220.7m in 1QFY10**
Revenue heaved 12.4% QoQ on higher global consumption (est. +8-10% p.a.) arising from H1N1 pandemic outbreak as well as the growing awareness in occupational safety and hygiene. However, operating margin decreased 1.7pts to 21.6% on the back of the unfavourable latex prices (est. RM7.75/kg) as a result of weaker US\$. Similarly, its America and European based associates suffered from weak US\$ with contribution plummeted -25% QoQ.
- **Improved in earnings forecasts**
We revised our FY10 and FY11 EPS estimates to 88.2sen and 93.7sen respectively on stronger than expected demand, anchoring on future capacity expansion. Given an additional 1.2bn pieces coming on stream in 3Q10, Supermax is well placed to capitalise on growing demand. The US healthcare reform, which expands health coverage to an additional 32m Americans, and China's pledge to spend 850bn yuan (US\$124bn) on healthcare between 2009 and 2011, could potentially lead to a higher glove consumption forward.
- **Reiterate Trading Buy.**
We raised our Target Price from RM5.53 to RM8.80 based on unchanged FY10 PER of 10x on higher FY10 EPS of 88.2sen. The trading buy call is in order with its differentiated own brand manufacturing, organic expansion strategies, improved liquidity, sound operation and attractive valuation. Risks to our recommendation include (i) surge in production capacity (ii) continued surge in RM and (iii) shortage of gas supply.

| Investment Data | | SUCB.MK | | Major shareholders : | | % |
|-----------------------------|--------------------|--------------------|--|---------------------------|--|---------------------|
| Bloomberg | | | | | | |
| Price | | RM6.90 | | Thai Kim Sim | | 20.4 |
| Expected capital gain | | 27.5% | | Tan Bee Geok | | 14.6 |
| Expected yield | | 2.6% | | Est. Free Float | | 65.0 |
| Expected return | | 30.1% | | | | |
| Market capitalisation | | RM1872.7m | | 12-month consensus | | |
| Share in issue @ RM0.50 par | | 271.4m | | Buys | | 8 |
| 52 week high/low | | RM7.45/RM1.18 | | Holds | | 0 |
| 3m average daily volume | | 3.5m shares | | Sells | | 1 |
| | | | | FY10 Estimate (EPS sen) | | 61.8 |
| | | | | FY11 Estimate (EPS sen) | | 70.9 |
| Stock Rating | Old | New | | | | |
| Trading Buy | Trading Buy | Trading Buy | | | | |
| Target Price | RM5.53 | RM8.80 | | KLCI | | 1,326.67 pts |

Financial Summary

| FY December (RM m) | 2008 | 2009 | 2010F | 2011F |
|--------------------|-------|-------|---------|---------|
| Turnover | 811.8 | 814.8 | 1,027.6 | 1,140.4 |
| EBIT | 98.9 | 144.2 | 222.0 | 244.0 |
| Pretax Profit | 52.0 | 152.1 | 252.8 | 269.1 |
| Core Net Profit | 63.7 | 129.8 | 239.4 | 254.3 |
| EPS(sen) | 17.7 | 48.4 | 88.2 | 93.7 |
| EPS Growth (%) | 21.9 | 173.8 | 82.3 | 6.2 |
| PER (x) | 31.0 | 11.3 | 7.8 | 7.4 |
| P/NTA (x) | 3.5 | 2.6 | 3.0 | 2.9 |
| Gross DPS (sen) | 3.2 | 11.0 | 17.6 | 19.0 |
| Dividend Yield (%) | 0.6 | 2.0 | 2.6 | 2.8 |
| ROE (%) | 11.7 | 26.6 | 37.8 | 40.1 |
| Net Gearing (x) | 0.9 | 0.3 | 0.3 | 0.5 |

Source : Alliance Research

| EARNINGS REVIEW | | | | | | |
|--------------------------|--------------------|--------------------|--------------------|----------------------|----------------------|--|
| FY Dec (RM m) | 2009 1Q | 2009 4Q | 2010 1Q | % YoY Chg | % QoQ Chg | Comments |
| Revenue | 192.4 | 196.4 | 220.7 | 14.7 | 12.4 | YoY growth due to higher ASP and improved sales volume from strong global demand. |
| Operating Expenses | (172.0) | (150.7) | (173.1) | 0.6 | 14.9 | - |
| Operating Profit | 20.4 | 45.7 | 47.6 | 133.3 | 4.2 | Greater operating profit attributed by the higher selling prices of gloves following the increase in latex cost passed through and demand outstripping supply. |
| Finance Costs | (5.0) | (3.1) | (3.7) | (26.0) | 19.4 | Lower interest rates for short term borrowings. |
| Pretax Profit | 23.5 | 50.6 | 54.3 | 131.1 | 7.3 | - |
| Taxation | (3.8) | (6.5) | (2.8) | -26.3 | -56.9 | |
| Net Profit | 19.7 | 44.1 | 51.5 | 161.4 | 16.8 | Net profit surged significantly due to the improved production efficiencies and cost savings. |
| EPS (sen) | 7.4 | 16.4 | 19.0 | 156.8 | 15.9 | |
| Operating Margin (%) | 10.6 | 23.3 | 21.6 | 11pts | -1.7pts | Weaker QoQ notwithstanding the larger revenue base (cost passed through via higher selling prices) while profit margin per glove remained intact. |
| Pretax Margin (%) | 12.2 | 25.8 | 24.6 | 12.4pts | -1.2pts | - |
| Net Margin (%) | 10.2 | 22.4 | 23.3 | 13.1pts | 0.9pts | - |
| Effective Tax Rate (%) | 16.2 | 12.8 | 5.2 | -11pts | -7.6pts | Lower than statutory income tax resulted from the reinvestment allowance claimed by certain subsidiary companies. |

Source : Alliance Research

Recommendation Framework

STOCK RECOMMENDATIONS

- OUTPERFORM** : The stock's total return is expected to exceed KLCI's total return by 10% or more in the next 12 months.
- MARKET PERFORM** : The stock's total return is expected to be within +10% or -10% of KLCI's total return.
- UNDERPERFORM** : The stock's total return is expected to be below KLCI's total return by 10% or more in the next 12 months.
- TRADING BUY** : The stock's total return is expected to exceed KLCI's total return by 10% or more within the next 3 months.
- TRADING SELL** : The stock's total return is expected to be below KLCI's total return by 10% or more within the next 3 months.
- NOT RATED** : Stock is not within our regular coverage

SECTOR RECOMMENDATIONS

- OVERWEIGHT** : The industry as defined by the analyst is expected to outperform the KLCI over the 12 months.
- NEUTRAL** : The industry as defined by the analyst is expected to perform in line with KLCI over the 12 months.
- UNDERWEIGHT** : The industry as defined by the analyst is expected to underperform the KLCI over the next 12 months.
- total return** = **capital gain + dividend yield**

Common Abbreviation

| | | |
|--|-------------------------------------|---|
| Adex = Advertising Expenditure | FCF = Free Cashflow | PEG = PE ratio to growth |
| bn = billion | FV = Fair Value | PER = PE ratio |
| BV = Book Value | FY = Financial Year | QoQ = Quarter on Quarter |
| CF = Cashflow | KLCI = Kuala Lumpur Composite Index | OP = Outperform |
| CAGR = Compounded Annual Growth rate | m = million | RM = Ringgit |
| Capex = Capital Expenditure | MoM = month on month | RM bn = RM billion |
| CY = Calendar Year | MP = Market Perform | RM m = RM million |
| Div yld = Dividend Yield | NAV = Net Assets Value | ROA = Return on Assets |
| DCF = Discounted Cashflow | NM = Not Meaningful | ROE = Return on Equity |
| | | ROSF = Return on shareholders funds |
| DPS = Dividend Per Share | NTA = Net Tangible Assets | TP = Target Price |
| EBIT = Earnings Before Interest & Tax | NR = Not Rated | UP = Under Perform |
| EBITDA = EBIT before Depreciation and Amortisation | p.a. = per annum | |
| EPS = Earnings per share | PAT = Profit after tax | WACC = Weighted Average Cost of Capital |
| | | YoY = Year on Year |
| EV = Enterprise Value | Pretax profit = Profit before tax | YTD = Year to date |
| 1QFY12/07 = 1 st Quarter for FY Dec 07 | PE = Price Earnings Ratio | |
| 2HFY12/07 = 2 nd Half for FY Dec 07 | | |

DISCLAIMER

This report has been prepared for information purposes only by Alliance Research Sdn Bhd (Alliance Research), a subsidiary of Alliance Investment Bank Berhad (AIBB). This report is strictly confidential and is meant for circulation to clients of Alliance Research and AIBB only or such persons as may be deemed eligible to receive such research report, information or opinion contained herein. Receipt and review of this report indicate your agreement not to distribute, reproduce or disclose in any other form or medium (whether electronic or otherwise) the contents, views, information or opinions contained herein without the prior written consent of Alliance Research.

This report is based on data and information obtained from various sources believed to be correct and reliable at the time of issuance of this report and any opinion expressed herein is subject to change without notice and may differ or be contrary to opinions expressed by Alliance Research's affiliates and/or related parties. Alliance Research does not make any guarantee, representation or warranty (whether express or implied) as to the accuracy, completeness, reliability or fairness of the data and information obtained from such sources as may be contained in this report. As such, neither Alliance Research nor its affiliates and/or related parties shall be held liable or responsible in any manner whatsoever arising out of or in connection with the reliance and usage of such data and information or third party references as may be made in this report (including, but not limited to any direct, indirect or consequential losses, loss of profits and damages).


The views expressed in this report reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendation(s) or view(s) in this report. Alliance Research prohibits the analyst(s) who prepared this report from receiving any compensation, incentive or bonus based on specific investment banking transactions or providing a specific recommendation for, or view of, a particular company.

This research report provides general information only and is not to be construed as an offer to sell or a solicitation to buy or sell any securities or other investments or any options, futures, derivatives or other instruments related to such securities or investments. In particular, it is highlighted that this report is not intended for nor does it have regard to the specific investment objectives, financial situation and particular needs of any specific person who may receive this report. Investors are therefore advised to make their own independent evaluation of the information contained in this report, consider their own individual investment objectives, financial situations and particular needs and consult their own professional advisers (including but not limited to financial, legal and tax advisers) regarding the appropriateness of investing in any securities or investments that may be featured in this report.

Alliance Research, its directors, representatives and employees or any of its affiliates or its related parties may, from time to time, have an interest in the securities mentioned in this report. Alliance Research, its affiliates and/or its related persons may do and/or seek to do business with the company(ies) covered in this report and may from time to time act as market maker or have assumed an underwriting commitment in securities of such company(ies), may sell or buy such securities from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory or underwriting services for or relating to such company(ies) as well as solicit such investment, advisory or other services from any entity mentioned in this report.

AIBB (which carries on, *inter alia*, corporate finance activities) and its activities are separate from Alliance Research. AIBB may have no input into company-specific coverage decisions (i.e. whether or not to initiate or terminate coverage of a particular company or securities in reports produced by Alliance Research) and Alliance Research does not take into account investment banking revenues or potential revenues when making company-specific coverage decisions.

In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the overriding issue of confidentiality, available upon request to enable an investor to make their own independent evaluation of the information contained herein.



Soh Meng Hui
Head of Research

Published and Printed by
ALLIANCE RESEARCH SDN BHD (290395-D)
Level 18, Menara Multi-Purpose
Capital Square
8, Jalan Munshi Abdullah
50100 Kuala Lumpur, Malaysia
Tel: +60(3) 2692 7788
Fax: +60(3) 2717 6622
Email: Allianceresearch@allianceinvestment.com.my